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2-(2-Cyano-2-phenylethyl)aziridines were converted into novel cis- and trans-2-chloromethyl-4-
phenylpiperidine-4-carbonitriles via alkylation with 1 bromo-2-chloroethane followed by microwave-
assisted 6-exo-tet cyclisation and regiospecific ring opening. The latter piperidines were used as 
eligible substrates for the synthesis of stereodefined 2-chloromethyl-, 2-hydroxymethyl- and 2-
carboxymethyl-4-phenylpiperidine-4-carboxylic acids, 2-hydroxymethyl-4-phenylpiperidine-4-
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carbonitriles, 3-hydroxy-5-phenylazepane-5-carbonitriles and 5-phenyl-2,7-
diazabicyclo[3.3.1]nonanes. 
Introduction 
The piperidine ring comprises an important structural unit in natural products and biologically active 
agents, and several thousands of piperidine compounds have been evaluated in clinical and 
preclinical studies.1 For these reasons, the search for general, efficient and stereoselective methods 
for piperidine synthesis has attracted the attention of the organic chemistry community for many 
years.2 In particular, 4-arylpiperidines represent an interesting class of biologically relevant 
compounds, about which numerous examples can be found in the patent literature.3 4-
Arylpiperidines are known to be useful as for example tachykinin antagonists for the treatment of 
pain and inflammation,4 and as -1a adrenergic receptor antagonists for the treatment of prostate 
disorders.5 Moreover, a number of drugs accommodate a 4-arylpiperidine unit in their structure, 
such as the analgesic meperidine 1 and the antipsychotic haloperidol 2.6  
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From a synthetic point of view, aziridines have proven to be excellent precursors for the preparation 
of functionalized piperidines. Indeed, intramolecular ring opening of aziridines by a remote amino 
moiety,7 and ring opening using Grignard reagents followed by elaboration of the tethered side 
chain8 are known strategies for the synthesis of piperidines starting from aziridines. Alternatively, 
[3+3]-cycloadditions of Pd-trimethylenemethane complexes with enantiomerically pure aziridines,9 
and aza-[2,3]-wittig rearrangements of vinylaziridines10 have also been used successfully in that 
respect.  
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In this paper, an efficient and direct method toward the novel 2-chloromethyl-4-phenylpiperidine-4-
carbonitrile scaffold is presented starting from 2-(2-cyano-2-phenylethyl)aziridines. Piperidine-4-
carbonitriles were employed successfully as substrates for the synthesis of a wide variety of 
stereodefined piperidines ranging from -amino acids and adipic acid derivatives to bicyclic 
piperidines with biological interest. 
 
Results and discussion 
The chemistry of 2-(2-cyanoethyl)aziridines remains an underexplored field of research, as only a few 
examples have been reported so far.11 Nevertheless, their synthetic usefulness has been 
demonstrated recently through the development of a versatile aziridine to cyclopropane ring 
transformation.12 In continuation of our interest in 2-(cyanoalkyl)aziridines12,13 as substrates in 
organic chemistry, a new protocol for the conversion of 2-(2-cyanoethyl)aziridines into functionalized 
piperidines was developed.  
1-Arylmethyl-2-(bromomethyl)aziridines 4, prepared from the corresponding benzaldehydes in a 
three-step procedure,14 are known to be excellent substrates for the synthesis of a variety of 2-
substituted 1-(arylmethyl)aziridines.12,15 Thus, 2-(bromomethyl)aziridines 4 were treated with 1.1 
equiv of -lithiated phenylacetonitrile in THF, affording 2-(2-cyano-2-phenylethyl)aziridines 5 as 
mixtures of diastereomers in good yields.12b With the intention to introduce a 2-chloroethyl group in 
-position with respect to the nitrile moiety in aziridines 5, the coupling between 1-bromo-2-
chloroethane and aminonitriles 5 was accomplished using 1.2 equiv of lithium diisopropylamide 
(LDA) in THF, furnishing novel 4-chloro-2-[1-(arylmethyl)aziridin-2-ylmethyl]-2-phenylbutyronitriles 6 
and 7 as a mixture of diastereomers ( 1/1) after one hour at 0°C (Scheme 1). Interestingly, 
diastereomers 6 could be easily isolated from the mixtures by crystallization from ethanol (15-40% 
yield), and diastereomers 7 were obtained in pure form through column chromatography on silica gel 
(hexane/EtOAc 3/1, 15-35% yield), allowing their full spectroscopic characterization. 
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The incorporation of a leaving group in -position with regard to the aziridine nitrogen atom renders 
aziridines 6 and 7 excellent substrates for a 6-exo-tet ring closure toward intermediate bicyclic 
aziridinium salts, suitable for further elaboration. It should be noted that the α-alkylation of nitriles 
using 2-chloro-1-haloethanes has been reported scarcely in the literature.16 
Interestingly, when heated under reflux in THF, no cyclisation of aziridines 6 and 7 toward piperidines 
took place. Clearly, a more polar solvent had to be used to allow intramolecular substitution and 
stabilize the intermediate bicyclic aziridinium ions. In accordance with the previously reported ring 
opening reactions of non-activated aziridines with benzyl bromide,12,15d,17 acetonitrile was used as a 
solvent, and the premised 6-exo-tet ring expansion reaction of aziridines 6 and 7 proceeded nicely 
under microwave irradiation at 136°C for 30 minutes or, alternatively, in DMSO for 3 hours under 
reflux applying conventional heating, affording 2-chloromethyl-4-phenylpiperidine-4-carbonitriles 9 
and 11 in excellent yields and purity (Scheme 2). The proposed mechanism involves an 
intramolecular substitution reaction, furnishing bicyclic aziridinium intermediates 8 and 10, followed 
by regiospecific ring opening by chloride at the less hindered aziridine carbon atom toward 2-
chloromethyl-4-phenylpiperidine-4-carbonitriles 9 and 11. 
Alternatively, trans-piperidines 11 were isolated more easily performing the 6-exo-tet ring expansion 
reaction on the diastereomeric mixture of aziridines 6 and 7, as trans-piperidines 11 could be 
crystallized from the reaction mixture using ethanol as a solvent [40-43% of piperidines 11 starting 
from 2-(2-cyano-2-phenylethyl)aziridines 5]. The relative stereochemistry of trans-2-chloromethyl-4-
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phenylpiperidine-4-carbonitriles 11 was unambiguously assigned by X-ray crystallographic analysis of 
piperidine 11b (See Supporting information). 
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2-Chloromethyl-4-phenylpiperidine-4-carbonitriles 9 and 11 exhibit a number of interesting 
structural characteristics, making them suitable substrates for further elaboration. For example, the 
presence of a cyano substituent at the 4-position of the piperidine backbone provides an entry into 
conformationally restricted amino acid derivatives. Additionally, the 2-chloromethyl moiety is 
susceptible to nucleophilic substitution reactions, both intra- and intermolecularly. 
- and -Amino acids are known to possess unique pharmacological properties, and their applications 
as building blocks for the corresponding - and -peptides make these compounds of high relevance 
in synthetic and medicinal chemistry.18 Besides their use in peptidomimetics, some -amino acids 
exhibit strong antibacterial activity (e.g. cispentacin),18b while -amino acids are used for the 
treatment of epilepsy, Parkinson disease and schizophrenia (e.g. GABA-analogues).19 In continuation 
of our interest in β-amino acid chemistry,20 intensive efforts were devoted to the development of 
new entries toward different constrained amino acids bearing a piperidine moiety in their structure 
starting from the corresponding nitriles. Due to the synthetic utility of nitriles as precursors of 
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carboxylic acids, esters and amides, the search for novel types of functionalized aminonitriles has 
become an important challenge in organic synthesis.21 
 
In a first part of this work, cis-piperidine 9c was hydrolyzed utilizing a HCl (3M)/HOAc (6M) mixture in 
water under microwave irradiation for 1 h at 150°C, resulting in the formation of an inseparable 
mixture of 2-(chloromethyl)- and 2-(hydroxymethyl)piperidines 12 and 13 (ratio 2/3). Subsequently, 
this mixture was treated with 2 equiv of LiOH in water for 30 minutes under reflux, followed by 
purification on Dowex (H+, 50X8-100), furnishing ammonium cis-1-(4-chlorobenzyl)-2-hydroxymethyl-
4-phenylpiperidine-4-carboxylate 14 as the sole reaction product in 80% yield (Scheme 3).  
Furthermore, trans-piperidine 11c was subjected to similar reaction conditions as cis-isomer 9c, i.e. 
hydrolysis using a HCl (3M)/HOAc (6M) mixture in water under microwave irradiation for 1 h 40 at 
150°C, furnishing trans-1-(4-chlorobenzyl)-2-chloromethyl-4-phenylpiperidine-4-carboxylic acid 15 in 
85% yield. Remarkably, no formation of the corresponding 2-(hydroxymethyl)piperidine was 
observed in the latter case, pointing to a considerable steric hindrance with regard to attack of the 
chlorinated carbon atom in piperidine 11c and 15. Stereodefined 4-phenylpiperidine-4-carboxylic 
acids 14 and 15 represent a new class of constrained -amino acids with biological relevance. 
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In light of the known biological importance of 3-aminoadipic acids,22 efforts were made for the 
preparation of novel conformational constrained analogues bearing a piperidine framework. Thus, 
cis-2-chloromethyl-4-phenylpiperidine-4-carbonitrile 9c was treated with 2 equiv of potassium 
cyanide in DMSO, furnishing the corresponding cis-2-cyanomethyl-4-phenylpiperidine-4-carbonitrile 
16 after 1 hour at 120°C in 92% yield. From a mechanistic viewpoint, piperidine 9c probably 
undergoes an intramolecular substitution reaction toward bicyclic aziridinium intermediate 8c, 
followed by regiospecific ring opening of this aziridinium salt by cyanide at the least hindered 
position, although direct SN2-substitution at the chlorinated atom cannot be excluded. Upon 3D-
analysis of intermediate 8c, the occurrence of a favorable - -stacking23 between both aromatic rings 
can be observed, which results in steric hindrance at the substituted aziridinium carbon atom. This 
effect might (partially) explain the exclusive attack at the unhindered position occurred, resulting in 
the selective formation of piperidine 16. Next, both cyano groups in compound 16 were transformed 
to the corresponding carboxylic acids by acid hydrolysis. Thus, treatment of dicyanopiperidine 16 
with a HCl (3M)/HOAc (6M) mixture in water gave rise to cis-2-carboxymethyl-1-(4-chlorobenzyl)-4-
8 
 
phenylpiperidine-4-carboxylic acid 17 in 95% yield as a new constrained analogue of 3-aminoadipic 
acid after reflux for 3 days (Scheme 4).  
Analogously, trans-1-(4-chlorobenzyl)-2-chloromethyl-4-phenylpiperidine-4-carbonitrile 11c was 
treated with 2 equiv of potassium cyanide in DMSO, resulting in a mixture of azepane-3,5-
dicarbonitrile 18 and 2-(cyanomethyl)piperidine-4-carbonitrile 19 (ratio 3/10) after 1 hour at 120 °C. 
Probably, due to the absence of - -stacking interaction, competition between attack at the 
unsubstituted and the substituted position in aziridinium intermediate 10c occurred, resulting in a 
mixture of azepane 18 and piperidine 19. Interestingly, azepane 18 could be easily transformed into 
the thermodynamically more stable piperidine 19 by heating the mixture of azepane 18 and 
piperidine 19 in DMSO at 120°C for 4 hours, affording 2-(cyanomethyl)piperidine 19 as the sole 
reaction product. Eventually, a nitrile to acid functional group transformation was performed in 
acidic medium (HCl (3M)/HOAc (6M) in H2O under reflux for 6 days), furnishing trans-2-
carboxymethyl-1-(4-chlorobenzyl)-4-phenylpiperidine-4-carboxylic acid 20 in 95% yield (Scheme 4). In 
summary, the above-described methodology allows the stereoselective preparation of both 
diastereomers of 2-carboxymethyl-4-phenylpiperidine-4-carboxylic acids 17 and 20 as biologically 
relevant targets, underlyning to the synthetic utility of this approach. 
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In addition to cyanide, acetate was used as an oxygen nucleophile for the synthesis of versatile -
amino alcohols using the same approach as described above. -Amino alcohols comprise an 
important class of compounds, as this moiety is found in a wide variety of biologically active alkaloids 
and peptides.24 Furthermore, -amino alcohols find applications as building blocks in the synthesis of 
various natural products and pharmaceuticals,25 and they are useful as chiral auxiliaries for 
asymmetric synthesis and catalysis.26  
cis-2-Chloromethyl-4-phenylpiperidine-4-carbonitriles 9a,c were treated with 2 equiv of sodium 
acetate in ethanol, affording cis-6-acetoxy-4-phenylazepane-4-carbonitriles 21 and cis-2-
acetoxymethyl-4-phenylpiperidine-4-carbonitriles 22 in a ratio of 1/2 after 2 hours under reflux 
(Scheme 5). Again, the reaction proceeded via intermediate bicyclic aziridinium salts 8a,c, followed 
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by preferential ring opening of the latter salts by acetate at the least hindered position. In this case, 
prolonged heating did not afford a single thermodynamic product, in contrast with the synthesis of 
aminonitriles 19 (Scheme 4). Furthermore, changing the solvent from ethanol to DMSO did not alter 
the isomeric ratio of the obtained products 21 and 22. Unfortunately, piperidines 22 and azepanes 21 
appeared to be inseparable by column chromatography on silica gel.  
Finally, acetates 21b and 22b were hydrolyzed using 2 equiv of lithium hydroxide in methanol under 
reflux for two hours, furnishing a mixture of cis-6-hydroxy-4-phenylazepane-4-carbonitrile 23 and cis-
2-hydroxymethyl-4-phenylpiperidine-4-carbonitrile 24 in 83% yield (Scheme 5). Piperidine 24 was 
separated through column chromatography on silica gel, providing a pure sample suitable for full 
spectroscopic characterization. 
Analogously, trans-piperidine 11c was subjected to a nucleophilic substitution reaction using sodium 
acetate in ethanol. In this case, the reaction proceeded more sluggishly, and only after 13 hours of 
reflux the substrate was consumed completely, affording a mixture of trans-6-acetoxy-4-
phenylazepane-4-carbonitrile 25 and trans-2-acetoxymethyl-4-phenylpiperidine-4-carbonitrile 26 
(25/26 3/1). Due to the long reaction time, partial formation (26%) of hydrolyzed products 27 and 28 
was observed as well under the given reaction conditions, making a full characterization of acetates 
25 and 26 impossible. In an attempt to shorten the reaction time, experiments were conducted using 
microwave irradiation, resulting in a reduction of the conversion time from 13 hours to 20 minutes at 
110°C using 2 equiv of NaOAc in EtOH at 200 Watt. Also in this case, the reaction mixture contained a 
mixture of both the acetates 25 and 26 as major components (74%) and alcohols 27 and 28 as minor 
impurities (26%).  
Again, functional group transformation of the acetate to corresponding alcohol was performed using 
2 equiv of LiOH in MeOH for 1 hour at reflux temperature, furnishing trans-6-hydroxy-4-
phenylazepane-4-carbonitrile 27 and trans-2-hydroxymethyl-4-phenylpiperidine-4-carbonitrile 28 in 
79% yield in a ratio of 3/1 (27/28). Carbonitrile 27 was separated via column chromatography on 
silica gel, affording a analytically pure sample.  
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It should be remarked that, starting from cis-piperidines 9a,c, the preferential formation of 
piperidines 22 was observed, whereas azepane 25 was the major reaction product if trans-piperidine 
11c was used as a substrate. This observation can partially be explained considering - -stacking in 
intermediate 8a,c, making an attack at the substituted aziridinium carbon atom more difficult due to 
steric hindrance. In addition, the polarizability of the nucleophiles might play an important role with 
regard to the regioselectivity, with cyanide being a strong and acetate a moderate nucleophile. 
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It should be noted that the ring enlargement of 2-(halomethyl)piperidines to 3-substituted azepanes 
via intermediate aziridinium salts has only been described sporadically in the literature.27 
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Finally, attempts were made to induce dehydrochlorination of 2-chloromethyl-4-phenylpiperidine-4-
carbonitriles 9 and 11, followed by migration of the double bound toward the thermodynamically 
more stable endocyclic position in order to form tetrahydropyridine-4-carbonitriles. Many bases 
(KOtBu, NaH, LDA) and solvents (THF, tBuOH, DMSO) were used, but complex reaction mixtures were 
obtained in all cases.  
Next to intermolecular nucleophilic substitutions with cyanide and acetate, an intramolecular 
reaction of cis-2-(chloromethyl)piperidines 9 was examined, taking advantage of the presence of a 
nitrile group at the 4-position as a masked aminomethyl moiety. Gratifyingly, treatment of 
piperidines 9 with 2 equiv of LiAlH4 in THF afforded 5-phenyl-2,7-diazabicyclo[3.3.1]nonanes 29 as 
single reaction products (Scheme 6, yields after purification). This conversion proceeded via the 
formation of an aminomethyl substituent through cyanide reduction, which subsequently induced an 
intramolecular 6-exo-tet ring closure toward 5-phenyl-2,7-diazabicyclo[3.3.1]nonanes 29 by attack of 
the free amino moiety onto the chlorinated carbon atom. At first sight, it cannot be excluded that 
this ring closing reaction proceeds via an intermediate bicyclic aziridinium salt 8 as described above, 
which might give rise to 6-phenyl-3,8-diazabicyclo[4.2.1]nonanes upon ring opening as an alternative 
for 5-phenyl-2,7-diazabicyclo[3.3.1]nonanes 29. In order to confirm the presence of a 
bicyclo[3.3.1]nonane instead of a bicyclo[4.2.1]nonane skeleton in the obtained reaction products, 
the free amino group at the 7-position was protected with a tert-butoxycarbonyl group using 1.1 
equiv of di-tert-butyl dicarbonate, 1.1 equiv of pyridine and DMAP (10 mol%) as the catalyst in CH2Cl2 
for 3 hours at room temperature (Scheme 6). This protection step resulted in substantial shifts of the 
signals of two CH2N carbon atoms in the Boc-protected amine 30 (46.39 ppm  42.84 ppm and 
58.68 ppm  53.19 ppm, 13C-NMR, CDCl3), whereas a less pronounced shift was observed for the 
CHN signal (52.09 ppm  50.82 ppm). These observations point into the direction of a 
bicyclo[3.3.1]nonane backbone. In order to resolve all doubts, X-ray analysis of compound 29c 
unambiguously assigned the 5-phenyl-2,7-diazabicyclo[3.3.1]nonane system present in compounds 
29 obtained through reduction of piperidines 9 by LiAlH4 (See supporting information).  
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In this way, a convenient entry toward the 2,7-diazabicyclo[3.3.1]nonane28 skeleton is presented 
through a straightforward approach. These compounds 29 can be regarded as novel aza-analogues of 
5-phenylmorphans 32, which act as opioid agonists or antagonists.29  
In analogy, trans-piperidines 11a,b were treated with 2 equiv of LiAlH4 in THF under refux for two 
hours, resulting in the formation of trans-4-aminomethyl-2-methyl-4-phenylpiperidines 31 in 60-65% 
yield (Scheme 6). The dechlorination of 2-(chloromethyl)piperidines 11 can take place via initial 
formation of an intermediate aziridinium salt 10 or via direct dechlorination, following either an ionic 
or a radical pathway.30 4-(Aminomethyl)piperidines have been patented as potent tachykinin 
antagonists for the treatment of pain and inflammation,4 and can be used for the treatment of 
epilepsy, anxiety and inflammatory diseases.31 
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In conclusion, a short and convenient approach toward novel cis- and trans-2-chloromethyl-4-
phenylpiperidine-4-carbonitriles is reported starting from 2-(2-cyano-2-phenylethyl)aziridines. 
Furthermore, the high synthetic flexibility of these piperidine building blocks was demonstrated by 
the synthesis of a variaty of stereodefined conformationally constrained amino acids -amino 
alcohols and unprecedented 2,7-diazabicyclo[3.3.1]nonanes. 
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Experimental Part 
General 
1H NMR spectra were recorded at 300 MHz (JEOL ECLIPSE+) with tetramethylsilane as internal 
standard. 13C NMR spectra were recorded at 75 MHz (JEOL ECLIPSE+). Mass spectra were recorded 
on an Agilent 1100 series mass spectrometer using either a direct inlet system (electron spray, 4000 
V) or LC-MS coupling (UV detector). IR spectra were recorded on a Perkin-Elemer Spectrum BX FT-IR 
spectrometer. All compounds were analysed in neat form with an ATR (Attenuated Total Reflectance) 
accessory. Melting points were measured using a Büchi B-540 apparatus and are uncorrected. 
Dichloromethane was distilled over calcium hydride, while diethyl ether and THF were distilled from 
sodium and sodium benzophenone ketyl before use. Microwave reactions were performed in a CEM 
Discover Microwave Reactor (200 Wmax) in a 80 ml sealed vessel using a fiber-optic temperature 
sensor. 
 
Synthesis of 4-chloro-2-[1-(arylmethyl)aziridin-2-ylmethyl]-2-phenylbutyronitriles 6 and 7. 
As a representative example, the synthesis of 4-chloro-2-[1-benzylaziridin-2-ylmethyl]-5-
phenylbutyronitriles 6a and 7a is described here. To an ice-cooled solution of diisopropylamine (60 
mmol, 1.2 equiv) in dry THF (75 ml) was added n-BuLi (1.2 equiv, 2.5 M) via a syringe under nitrogen 
atmosphere, and the resulting solution was stirred for 15 minutes at 0°C. Subsequently, a solution of 
1-benzyl-2-(2-cyano-2-phenylethyl)aziridine 5a (50 mmol)12b in THF (20 ml) was added via a syringe at 
0°C, and the resulting solution was stirred for 1 h at 0°C. Finally, 1-bromo-2-chloroethane (55 mmol, 
1.1 equiv) was added via a syringe at 0°C, and the reaction mixture was stirred for 1 h at 0°C under 
nitrogen atmosphere. The reaction mixture was poured into a saturated NH4Cl solution (75 ml) and 
was extracted with Et2O (3 × 75 ml). Drying (MgSO4), filtration of the drying agent and evaporation of 
the solvent in vacuo afforded 4-chloro-2-[1-benzylaziridine-2-ylmethyl]-2-phenylbutyronitriles 6a and 
7a as a mixture of isomers ). Isolation of the mixture of (2R,2’R)- and (2S,2’S)-isomers 6a was 
realized by means of a selective crystallization from ethanol, whereas the (2R,2’S)- and (2S,2’R)-
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isomers 7a were obtained by column chromatography on silica gel (hexane/EtOAc 3/1). (2R, 2’R)- 
and (2S, 2’S)-2-[1-Benzylaziridin-2-ylmethyl]-4-chloro-2-phenylbutyronitrile 6a. (38%) White 
Crystals. Mp = 79.7°C. Rf = 0.21 (hexane/EtOAc 3/1). 
1H NMR (CDCl3): δ 1.39-1.47 (2H, m); 1.75 (1H, d, 
J = 2.8 Hz); 2.03 and 2.26 (2H, 2×dd, J = 14.0, 5.8, 5.2 Hz); 2.38 (1H, ddd, J = 13.7, 11.3, 5.1 Hz); 2.52 
(1H, ddd, J = 13.7, 11.1, 5.4 Hz); 2.92 and 3.23 (2H, 2×d, J = 12.9 Hz); 3.19 (1H, ddd, J = 11.0, 10.9, 4.8 
Hz); 3.56 (1H, ddd, J = 11.1, 11.0, 5.3 Hz); 7.13-7.52 (10H, m). 13C NMR (CDCl3); δ 33.8 (CH2); 35.2 
(CH); 39.4 (CH2); 43.2 (CH2); 44.2 (CH2); 46.1 (C); 64.3 (CH2); 121.4 (C); 126.1 (CH); 127.3 (CH); 128.3 
(CH); 128.5 (CH); 128.6 (CH); 129.4 (CH); 136.4 (C); 138.7 (C). IR (cm-1): νCN = 2236. MS (70 eV): m/z 
(%): 325/7 (M++1, 100). Anal. Calcd for C20H21ClN2: C 73.95; H 6.52; N 8.62. Found: C 74.23; H 6.87; N 
8.49. (2S, 2’R)- and (2R, 2’S)-2-[1-Benzylaziridin-2-ylmethyl]-4-chloro-2-phenylbutyronitrile 7a. 
(15%) Yellow oil. Rf = 0.13 (hexane/EtOAc 3/1). 
1H NMR (CDCl3): δ 1.32 (1H, d, J = 6.1 Hz); 1.40 (1H, d, 
J = 3.9 Hz); 1.63-1.70 (1H, m); 2.02 and 2.10 (2H, 2×dd, J = 14.3, 7.2, 5.5 Hz); 2.34 (1H, ddd, J = 13.8, 
11.3, 5.1 Hz); 2.48 (1H, ddd, J = 13.8, 11.0, 5.5 Hz); 3.14 (1H, ddd, J = 11.0, 11.0, 5.0 Hz); 3.46 (1H, 
ddd, J = 11.0, 11.0, 5.6 Hz); 3.19 and 3.64 (2H, 2×d, J = 12.7 Hz); 7.23-7.47 (1H, m). 13C NMR (CDCl3); δ 
33.3 (CH2); 35.4 (CH); 39.4 (CH2); 42.4 (CH2); 44.7 (CH2); 46.1 (C); 64.6 (CH2); 121.1 (C); 125.8 (CH); 
127.5 (CH); 128.5 (CH); 128.6 (CH); 128.6 (CH); 129.3 (CH); 137.1 (C); 138.5 (C). IR (cm-1): νCN = 2237. 
MS (70 eV): m/z (%): 325/7 (M++1, 100). Anal. Calcd for C20H21ClN2: C 73.95; H 6.52; N 8.62. Found: C 
74.20; H 6.72; N 8.51. 
 
Synthesis of cis-1-arylmethyl-2-chloromethyl-4-phenylpiperidine-4-carbonitriles 9. As a 
representative example, the synthesis of cis-1-benzyl-2-chloromethyl-4-phenylpiperidine-4-
carbonitrile 9a is described here. A solution of 2-[1-benzylaziridin-2-ylmethyl]-4-chloro-2-
phenylbutyronitrile 6a (20 mmol) in acetonitrile (20 ml) was placed in a 80 ml sealed glass vessel, 
provided with an appropriate stirring bar and subjected to microwave conditions (136°C, 30 
minutes). Afterwards, evaporation of the solvent afforded cis-1-benzyl-2-chloromethyl-4-
phenylpiperidine-4-carbonitrile 9a in quantitative yield. cis-1-Benzyl-2-chloromethyl-4-
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phenylpiperidine-4-carbonitrile 9a. (99%) Yellow oil. Rf = 0.15 (hexane/EtOAc 3/1). 
1H NMR (CDCl3): δ 
2.11-2.35 (3H, m); 2.56-2.66 (2H, m); 2.98 (1H, ddd, J = 12.8, 9.5, 3.2 Hz); 3.16 (1H, m); 3.66 and 3.87 
(2H, 2×d, J = 13.5 Hz); 3.87 and 4.19 (2H, 2×dd, J = 11.3, 9.1, 4.7 Hz); 7.23-7.52 (10H, m). 13C NMR 
(CDCl3); δ 35.0 (CH2); 36.1 (CH2); 38.5 (C); 42.3 (CH2); 44.2 (CH2); 58.4 (CH2); 58.5 (CH); 124.0 (C); 
126.2 (CH); 127.5 (CH); 128.3 (CH); 128.6 (CH); 129.3 (CH); 138.6 (C); 139.4 (C). IR (cm-1): νCN = 2231. 
MS (70 eV): m/z (%): 325/7 (M++1, 100). Anal. Calcd for C20H21ClN2: C 73.95; H 6.52; N 8.62. Found: C 
74.31; H 6.74; N 8.49. 
 
Synthesis of trans-1-arylmethyl-2-chloromethyl-4-phenylpiperidine-4-carbonitriles 11. As a 
representative example, the synthesis of trans-1-benzyl-2-chloromethyl-4-phenylpiperidine-4-
carbonitrile 11a is described here. A solution of 2-[1-benzylaziridin-2-ylmethyl]-4-chloro-2-
phenylbutyronitrile 7a (17.5 mmol) in acetonitrile (20 ml) was placed in a 80 ml sealed glass vessel, 
provided with an appropriate stirring bar and subjected to microwave conditions (136°C, 30 
minutes). Afterwards, evaporation of the solvent afforded trans-1-benzyl-2-chloromethyl-4-
phenylpiperidine-4-carbonitrile 11a in a quantitative yield. trans-1-Benzyl-2-chloromethyl-4-
phenylpiperidine-4-carbonitriles 11a. (99%) White Crystals. Mp = 115.1°C. Rf = 0.21 (hexane/EtOAc 
3/1). 1H NMR (CDCl3): δ 1.98-2.02 (2H, m); 2.14-2.28 (2H, m); 2.57 (1H, ddd, J = 12.5, 8.4, 6.2 Hz); 
2.95-3.05 (2H, m); 3.18 (1H, d, J = 13.2 Hz); 3.63 and 3.96 (2H, 2×dd, J = 12.1, 5.0, 1.7 Hz); 4.21 (1H, d, 
J = 13.2 Hz); 7.23-7.51 (10H, m). 13C NMR (CDCl3); δ 35.9 (CH2); 40.9 (CH2); 43.3 (C); 46.6 (CH2); 49.3 
(CH2); 57.3 (CH2); 59.1 (CH); 122.2 (C); 125.7 (CH); 127.4 (CH); 128.4 (CH); 128.6 (CH); 129.2 (CH); 
138.4 (C); 139.9 (C). IR (cm-1): νCN = 2233. MS (70 eV): m/z (%): 325/7 (M
++1, 100). Anal. Calcd for 
C20H21ClN2: C 73.95; H 6.52; N 8.62. Found: C 74.11; H 6.68; N 8.66.  
 
Synthesis of ammonium cis-1-(4-chlorobenzyl)-2-hydroxymethyl-4-phenylpiperidine-4-carboxylate 
14. To a solution of cis-1-(4-chlorobenzyl)-2-chloromethyl-4-phenylpiperidine-4-carbonitrile (1.4 
mmol) 9c in water (5 ml) was added 3M hydrochloric acid (1.62 ml) and 6M acetic acid (3.42 ml). The 
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mixture was placed in a 80 ml sealed glass vessel, provided with an appropriate stirring bar and 
subjected to microwave conditions (150°C, 1 hour). Afterwards, the solvent was evaporated under 
high vacuum, and the residue was redisolved in water (10 ml). Subsequently, LiOH (2.4 mmol, 2 
equiv) was added to this solution, after which the resulting mixture was heated under reflux for 30 
minutes. Isolation of ammonium cis-1-(4-chlorobenzyl)-2-hydroxymethyl-4-phenylpiperidine-4-
carboxylate 14 was realized by means of ion exchange chromatography on Dowex H+ (50X8-100). 
Ammonium cis-1-(4-chlorobenzyl)-2-hydroxymethyl-4-phenylpiperidine-4-carboxylate 14. 
(80%)White Crystals. Mp = 228.3°C. 1H NMR (CD3OD): δ 2.14 (1H, ddd, J = 14.9, 11.6, 3.6 Hz); 2.26 
(1H, dd, J = 14.9, 11.0 Hz); 2.45 (1H, dt, J = 12.2, 2.4 Hz); 2.58 (1H, d (broad), J = 14.9 Hz); 2.74 (1H, d 
(broad), J = 14.9 Hz); 2.83-2.86 (1H, m); 2.95 (1H, dt, J = 12.2, 3.6 Hz); 3.57 (1H, d, J = 13.2 Hz); 3.78 
and 3.93 (2H, 2×dd, J = 12.1, 5.0, 3.9 Hz); 4.36 (1H, d, J = 13.2 Hz); 7.16-7.50 (9H, m). 13C NMR 
(CD3OD); δ 30.6 (CH2); 34.3 (CH2); 41.1 (C); 48.5 (CH2); 55.6 (CH2); 60.8 (CH); 61.3 (CH2); 126.0 (CH); 
127.0 (CH); 128.2 (CH); 128.4 (CH); 131.8 (CH); 126.8 (C); 134.2 (C); 141.5 (C); 180.5 (C). IR (cm-1): νOH 
= 3365, νCO = 1579. MS (70 eV): m/z (%): 360/2 (M
++1, 100). Anal. Calcd for C20H25ClN2O3: C 63.74; H 
6.69; N 7.43. Found: C 63.86; H 6.81; N 7.23. 
 
Synthesis of trans-1-(4-chlorobenzyl)-2-chloromethyl-4-phenylpiperidine-4-carboxylic acid 15. To a 
solution of trans-1-(4-chlorobenzyl)-2-chloromethyl-4-phenylpiperidine-4-carbonitrile (1.4 mmol) 11c 
in water (5 ml) was added 3M hydrochloric acid (1.62 ml) and 6M acetic acid (3.42 ml). The mixture 
was placed in a 80 ml sealed glass vessel, provided with an appropriate stirring bar and subjected to 
microwave conditions (150°C, 1h40 hour). Afterwards, the solvent was evaporated under high 
vacuum, affording trans-1-(4-chlorobenzyl)-2-chloromethyl-4-phenylpiperidine-4-carboxylic acid 15 
in good yield and high purity (> 95% based on NMR analysis). trans-1-(4-Chlorobenzyl)-2-
chloromethyl-4-phenylpiperidine-4-carboxylic acid 15. (85%) White Crystals. Mp = 216.6°C. 1H NMR 
(CD3OD): δ 1.92-2.03 (1H, m); 2.20 (1H, dd, J = 14.5, 12.4 Hz); 2.73 (1H, d (broad), J = 14.3 Hz); 2.89 
(1H, dd, J = 14.5, 2.5 Hz,); 3.10 (1H, dt, J = 13.3, 2.5 Hz); 3.34 (1H, ddd, J = 13.3, 4.0, 2.6 Hz); 3.81-3.86 
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(1H, m); 4.05 (1H, dd, J = 13.4, 2.5 Hz); 4.13 (1H, d, J = 13.2 Hz); 4.38-4.42 (1H, m); 4.70 (1H, d, J = 
13.2 Hz); 7.18-7.48 (9H, m). 13C NMR (CD3OD); δ 30.0 (CH2); 35.2 (CH2); 42.8 (CH2); 48.2 (C); 49.8 
(CH2); 55.2 (CH2); 62.3 (CH); 125.1 (CH); 127.7 (CH); 128.7 (CH); 129.3 (CH); 133.2 (CH); 127.4 (C); 
136.3 (C); 141.0 (C); 174.4 (C). IR (cm-1): νOH = 3362, νCO = 1715. MS (70 eV): m/z (%): 378/80/82 
(M++1, 100). Anal. Calcd for C20H21Cl2NO2: C 63.50; H 5.60; N 3.70. Found: C 63.77; H 5.95; N 3.51. 
 
Synthesis of cis-1-(4-chlorobenzyl)-2-cyanomethyl-4-phenylpiperidine-4-carbonitrile 16. To a 
solution of cis-1-(4-chlorobenzyl)-2-chloromethyl-4-phenylpiperidine-4-carbonitrile (1.0 mmol) 9c in 
DMSO (10 ml) was added potassium cyanide (2 mmol, 2 equiv), and the resulting solution was heated 
for 1 hour at 120°C. The reaction mixture was poured into water (10 ml) and extracted with Et2O (3 × 
10 ml). Drying (MgSO4), filtration of the drying agent, and evaporation of the solvent in vacuo 
afforded cis-1-(4-chlorobenzyl)-2-cyanomethyl-4-phenylpiperidine-4-carbonitrile 16, which was 
isolated in pure form by means of column chromatography on silica gel (hexane/EtOAc 3/1). cis-1-(4-
Chlorobenzyl)-2-cyanomethyl-4-phenylpiperidine-4-carbonitrile 16. (92%) White Crystals. Mp = 
135.3°C. Rf = 0.16 (hexane/EtOAc 3/1). 
1H NMR (CDCl3): δ 2.08-2.25 (2H, m); 2.35 and 2.45 (2H, 2×dd, 
J = 14.4, 5.0, 3.6 Hz); 2.55-2.62 (1H, m); 2.80 (1H, dd, J = 17.1, 5.5 Hz); 2.82-2.90 (1H, m); 3.09 (1H, dd, 
J = 17.1, 8.3 Hz); 3.29-3.37 (1H, m); 3.55 and 3.72 (2H, 2×d, J = 13.2 Hz); 7.22-7.48 (9H, m). 
13C NMR 
(CDCl3); δ 16.9 (CH2); 34.9 (CH2); 38.2 (CH2); 38.4 (C); 43.5 (CH2); 54.1 (CH); 57.6 (CH2); 118.6 (C); 
123.9 (C); 126.1 (CH); 128.6 (CH); 128.8 (CH); 129.4 (CH); 130.0 (CH); 132.2 (C); 136.6 (C); 138.9 (C). IR 
(cm-1): νCN = 2249. MS (70 eV): m/z (%): 350/2 (M
++1, 100). Anal. Calcd for C21H20ClN3: C 72.09; H 5.76; 
N 12.01. Found: C 72.19; H 5.84; N 11.93. 
 
Synthesis of cis-2-carboxymethyl-1-(4-chlorobenzyl)-4-phenylpiperidine-4-carboxylic acid 17. To a 
solution of cis-1-(4-chlorobenzyl)-2-cyanomethyl-4-phenylpiperidine-4-carbonitrile 16 (0.43 mmol) in 
water (5 ml) was added 3M hydrochloric acid (1.62 ml) and 6M acetic acid (3.42 ml) at room 
temperature, and the resulting solution was heated under reflux for 3 days. Isolation of cis-2-
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carboxymethyl-1-(4-chlorobenzyl)-4-phenylpiperidine-4-carboxylic acid 17 was performed by 
crystallization from the resulting solution upon standing at room temperature for 2 days. cis-2-
Carboxymethyl-1-(4-chlorobenzyl)-4-phenylpiperidine-4-carboxylic acid 17. (95%) White Crystals. 
Mp = 169.5°C. 1H NMR (CD3OD): δ 2.26-2.37 (1H, m); 2.39 (1H, dd, J = 15.4, 11.6 Hz); 2.78-2.90 (2H, 
m); 3.04 (1H, dd, J = 17.3, 7.4 Hz); 3.14 (1H, d, J = 15.4 Hz); 3.24-3.31 (2H, m); 3.56-3.63 (1H, m); 3.98 
and 4.72 (2H, 2×d, J = 13.2 Hz); 7.32-7.58 (9H, m). 13C NMR (CD3OD); δ 29.1 (CH2); 34.7 (CH2); 35.0 
(CH2); 46.8 (C); 48.4 (CH2); 55.8 (CH2); 58.0 (CH); 127.1 (CH); 127.7 (CH); 127.7 (CH); 129.1 (CH); 132.9 
(CH); 136.0 (C); 136.8 (C); 171.8 (C); 175.1 (C). IR (cm-1): νOH = 3010 νCO = 1724. MS (70 eV): m/z (%): 
388/90 (M++1, 100). Anal. Calcd for C21H22ClNO4: C 65.03; H 5.72; N 3.61. Found: C 65.46; H 5.92; N 
3.48. 
 
Synthesis of trans-1-(4-chlorobenzyl)-5-phenylazepane-3,5-dicarbonitrile 18. To a solution of trans-
1-(4-chlorobenzyl)-2-chloromethyl-4-phenylpiperidine-4-carbonitrile 11c (0.5 mmol) in DMSO (10 ml) 
was added potassium cyanide (1 mmol, 2 equiv), and the resulting solution was heated at 120°C for 1 
hour. The reaction mixture was poured into water (10 ml) and extracted with Et2O (3 × 10 ml). Drying 
(MgSO4), filtration of the drying agent, and evaporation of the solvent in vacuo afforded a mixture of 
trans-1-(4-chlorobenzyl)-5-phenylazepane-3,5-dicarbonitrile 18 and trans-1-(4-chlorobenzyl)-2-
cyanomethyl-4-phenylpiperidine-4-carbonitrile 19 in a  3/10 ratio (18/19). trans-1-(4-Chlorobenzyl)-
5-phenylazepane-3,5-dicarbonitrile 18 was isolated in pure form by means of column 
chromatography on silica gel (hexane/EtOAc 3/1). trans-1-(4-Chlorobenzyl)-5-phenylazepane-3,5-
dicarbonitrile 18. (21%) Yellow oil. Rf = 0.22 (hexane/EtOAc 3/1). 
1H NMR (CDCl3): δ 2.18-2.25 (2H, 
m); 2.45-2.51 (2H, m); 2.87-3.01 (2H, m); 3.03-3.24 (3H, m); 3.71 and 3.81 (2H, 2×d, J = 13.2 Hz); 7.26-
7.50 (9H, m). 13C NMR (CDCl3); δ 29.9 (CH); 40.7 (CH2); 42.2 (CH2); 44.9 (C); 51.8 (CH2); 55.0 (CH2); 62.0 
(CH2); 120.5 (C); 121.0 (C); 125.1 (CH); 128.5 (CH); 128.9 (CH); 129.4 (CH); 130.2 (CH); 133.4 (C); 136.8 
(C); 141.2 (C). IR (cm-1): νCN = 2238. MS (70 eV): m/z (%): 350/2 (M
++1, 100). Anal. Calcd for C21H20ClN3: 
C 72.09; H 5.76; N 12.01. Found: C 71.90; H 5.86; N 12.17. 
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Synthesis of trans-1-(4-chlorobenzyl)-2-cyanomethyl-4-phenylpiperidine-4-carbonitrile 19. To a 
solution of trans-1-(4-chlorobenzyl)-2-chloromethyl-4-phenylpiperidine-4-carbonitrile (1.0 mmol) 11c 
in DMSO (10 ml) was added potassium cyanide (2 mmol, 2 equiv), and the resulting solution was 
heated for 5 hours at 120°C. The reaction mixture was poured into water (10 ml) and extracted with 
Et2O (3 × 10 ml). Drying (MgSO4), filtration of the drying agent, and evaporation of the solvent in 
vacuo afforded trans-1-(4-chlorobenzyl)-2-cyanomethyl-4-phenylpiperidine-4-carbonitrile 19, which 
was isolated in pure form by means of column chromatography on silica gel (hexane/EtOAc 3/1). 
trans-1-(4-Chlorobenzyl)-2-cyanomethyl-4-phenylpiperidine-4-carbonitrile 19. (88%) White Crystals. 
Mp = 129.9°C. Rf = 0.16 (hexane/EtOAc 3/1). 
1H NMR (CDCl3): δ 2.03-2.08 (2H, m); 2.11-2.25 (2H, m); 
2.50-2.59 (2H, m); 2.94-3.08 (3H, m); 3.18 and 4.12 (2H, 2×d, J = 12.9 Hz); 7.26-7.52 (9H, m). 13C NMR 
(CDCl3); δ 23.3 (CH2); 35.6 (CH2); 42.7 (CH2); 43.2 (C); 49.3 (CH2); 55.0 (CH); 57.1 (CH2); 116.7 (C); 
121.7 (C); 125.6 (CH); 128.6 (CH); 128.8 (CH); 129.3 (CH); 130.3 (CH); 133.4 (C); 136.4 (C); 139.1 (C). IR 
(cm-1): νCN = 2248. MS (70 eV): m/z (%): 350/2 (M
++1, 100). Anal. Calcd for C21H20ClN3: C 72.09; H 5.76; 
N 12.01. Found: C 72.21; H 5.93; N 11.92. 
 
Synthesis of trans-2-carboxymethyl-1-(4-chlorobenzyl)-4-phenylpiperidine-4-carboxylic acid 20. To 
a solution of trans-1-(4-chlorobenzyl)-2-cyanomethyl-4-phenylpiperidine-4-carbonitrile 19 (0,65 
mmol) in water (5 ml) was added 3M hydrochloric acid (1.62 ml) and 6M acetic acid (3.42 ml) at room 
temperature, and the resulting solution was heated under reflux for 6 days. Isolation of trans-2-
carboxymethyl-1-(4-chlorobenzyl)-4-phenylpiperidine-4-carboxylic acid 20 was performed by 
crystallization from the resulting solution upon standing at room temperature for 2 days. trans-2-
Carboxymethyl-1-(4-chlorobenzyl)-4-phenylpiperidine-4-carboxylic acid 20. (95%) White Crystals. 
Mp = 243.3°C. 1H NMR ((CD3)2SO): δ 1.88-2.02 (2H, m); 2.57 (1H, d, J = 13.0 Hz); 2.74-2.82 (2H, m); 
2.92 (1H, t, J = 13.0 Hz); 3.12-3.25 (2H, m); 3.56-3.64 (1H, m); 4.11 and 4.53 (2H, 2×d, J = 13.0 Hz); 
7.24-7.53 (9H, m). 13C NMR ((CD3)2SO); δ 30.0 (CH2N); 36.9 (CH2); 37.3 (CH2); 48.3 (C); 49.3 (CH2); 54.4 
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(CH2); 58.8 (CH); 125.7 (CH); 128.2 (CH); 129.4 (CH); 129.5 (CH); 133.7 (CH); 135.0 (C); 141.9 (C); 171.8 
(C); 174.6 (C). IR (cm-1): νOH = 3240, νCO = 1742, 1692. MS (70 eV): m/z (%): 388/90 (M
++1, 100). Anal. 
Calcd for C21H22ClNO4: C 65.03; H 5.72; N 3.61. Found: C 65.41; H 5.94; N 3.39. 
 
Synthesis of cis-6-acetoxy-1-arylmethyl-4-phenylazepane-4-carbonitriles 21 and cis-2-
acetoxymethyl-1-arylmethyl-4-phenylpiperidine-4-carbonitriles 22. As a representative example, 
the synthesis of cis-6-acetoxy-1-(4-chlorobenzyl)-4-phenylazepane-4-carbonitrile 21b and cis-2-
acetoxymethyl-1-(4-chlorobenzyl)-4-phenylpiperidine-4-carbonitrile 22b is presented here. To a 
solution of cis-1-(4-chlorobenzyl)-2-chloromethyl-4-phenylpiperidine-4-carbonitrile 9c (0.95 mmol) in 
ethanol (10 ml) was added sodium acetate (1.9 mmol, 2 equiv), and the resulting solution was heated 
under reflux for 2 hours. The reaction mixture was poured into water (10 ml) and extracted with Et2O 
(3 × 10 ml). Drying (MgSO4), filtration of the drying agent, and evaporation of the solvent in vacuo 
afforded cis-6-acetoxy-1-(4-chlorobenzyl)-4-phenylazepane-4-carbonitrile 21b and cis-2-
acetoxymethyl-1-(4-chlorobenzyl)-4-phenylpiperidine-4-carbonitrile 22b. Isolation of pure samples of 
azepane 21b and piperidine 22b from the mixture by means of column chromatography on silica gel 
(hexane/EtOAc 9/1) was not possible , and spectral data were derived from the mixture of 21b and 
22b.  
cis-6-Acetoxy-1-(4-chlorobenzyl)-4-phenylazepane-4-carbonitrile 21b. Spectral data derived from a 
mixture of diastereomers. Yellow oil. Rf = 0.16 (hexane/EtOAc 9/1). 
1H NMR (CDCl3): δ 2.03 (3H, s); 
2.17-2.28 (2H, m); 2.49-2.56 (2H, m); 2.81-3.14 (4H, m); 3.62 and 3.70 (2H, 2×d, J = 13.8 Hz); 5.13-
5.22 (1H, m); 7.21-7.54 (9H, m). 13C NMR (CDCl3); δ 21.3 (CH3); 40.6 (CH2); 42.3 (C); 43.4 (CH2); 53.1 
(CH2); 57.5 (CH2); 62.3 (CH2); 70.4 (CH); 122.9 (C); 125.4 (CH); 128.0 (CH); 128.3 (CH); 130.3 (CH); 
132.9 (C); 137.6 (C); 141.9 (C); 170.5 (C). IR (cm-1): νCO = 1736 νCN = 2232. MS (70 eV): m/z (%): 383/5 
(M++1, 100). 
cis-2-Acetoxymethyl-1-(4-chlorobenzyl)-4-phenylpiperidine-4-carbonitrile 22b. Spectral data 
derived from a mixture of diastereomers. Yellow oil. Rf = 0.16 (hexane/EtOAc 9/1). 
1H NMR (CDCl3): δ 
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2.06 (3H, s); 2.08-2.28 (2H, m); 2.36 (2H, d, J = 5.0 Hz); 2.49-2.56 (1H, m); 2.81-3.04 (1H, m); 3.07-3.14 
(1H, m); 3.59 and 3.82 (2H, 2×d, J = 13.8 Hz); 4.50 and 4.57 (2H, 2×dd, J = 11.9, 6.1, 5.8 Hz); 7.21-7.54 
(9H, m). 13C NMR (CDCl3); δ 21.5 (CH3); 35.0 (CH2); 37.0 (CH2); 38.6 (C); 44.6 (CH2N); 56.0 (CH); 57.7 
(CH2); 62.6 (CH2); 123.9 (C); 126.2 (CH); 128.6 (CH); 129.2 (CH); 129.8 (CH); 130.0 (CH); 132.8 (C); 
137.6 (C); 139.3 (C); 170.8 (C). IR (cm-1): νCO = 1736 νCN=2232. MS (70 eV): m/z (%): 383/5 (M
++1, 100). 
 
Synthesis of cis-1-(4-chlorobenzyl)-2-hydroxymethyl-4-phenylpiperidine-4-carbonitrile 24. To a 
solution of cis-2-acetoxymethyl-1-(4-chlorobenzyl)-4-phenylpiperidine-4-carbonitrile 22b and cis-6-
acetoxy-1-(4-chlorobenzyl)-4-phenylazepane-4-carbonitriles 21b (0.6 mmol) in methanol (10 ml) was 
added lithium hydroxide (1.3 mmol, 2 equiv), and the resulting solution was heated under reflux for 2 
hours. The reaction mixture was poured into water (10 ml) and extracted with Et2O (3 × 10 ml). 
Drying (MgSO4), filtration of the drying agent, and evaporation of the solvent in vacuo afforded a 
mixture of cis-1-(4-chlorobenzyl)-6-hydroxy-4-phenylazepane-4-carbonitrile 23 and cis-1-(4-
chlorobenzyl)-2-hydroxymethyl-4-phenylpiperidin-4-carbonitrile 24 in a ratio of 33-36/64-67 (23/24). 
The major isomer cis-1-(4-chlorobenzyl)-2-hydroxymethyl-4-phenylpiperidin-4-carbonitrile 24 was 
isolated and purified by means of column chromatography on silica gel (hexane/EtOAc 1/1). cis-1-(4-
Chlorobenzyl)-2-hydroxymethyl-4-phenylpiperidine-4-carbonitrile 24. (55%) Yellow oil. Rf = 0.34 
(hexane/EtOAc 1/1). 1H NMR (CDCl3): δ 2.10 (1H, ddd, J = 13.8, 7.2, 2.8 Hz); 2.29-2.40 (3H, m); 2.50 
(1H, ddd, J = 13.4, 7.2, 3.2 Hz); 2.91 (1H, pent., J = 5.6 Hz); 3.03 (1H, ddd, J = 13.4, 8.7, 2.8 Hz); 3.51 
and 3.89 (2H, 2×d, J = 13.5 Hz); 3.88 and 4.00 (2H, 2×dd, J = 11.6, 6.1, 5.5 Hz); 7.22-7.50 (9H, m). 13C 
NMR (CDCl3); δ 33.0 (CH2); 35.1 (CH2); 38.4 (C); 44.4 (CH2); 57.4 (CH); 58.1 (CH2); 60.9 (CH2); 124.3 (C); 
126.4 (CH); 128.4 (CH); 128.8 (CH); 129.3 (CH); 130.0 (CH); 133.2 (C); 137.2 (C); 138.9 (C). IR (cm-1): 
νOH = 3435 νCN = 2232. MS (70 eV): m/z (%): 341/3 (M
++1, 100). Anal. Calcd for C20H21ClN2O: C 70.48; H 
6.21; N 8.22. Found: C 70.69; H 6.44; N 8.05. 
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Synthesis of trans-1-(4-chlorobenzyl)-6-hydroxy-4-phenylazepane-4-carbonitrile 27. To a solution of 
trans-1-(4-chlorobenzyl)-2-chloromethyl-4-phenylpiperidine-4-carbonitrile 11c (0.95 mmol) in 
ethanol (10 ml) was added sodium acetate (1.9 mmol, 2 equiv), and the resulting solution was heated 
under reflux for 13 hours. The reaction mixture was poured into water (10 ml) and extracted with 
Et2O (3 × 10 ml). Drying (MgSO4), filtration of the drying agent and evaporation of the solvent 
afforded trans-6-acetoxy-1-(4-chlorobenzyl)-4-phenylazepane-4-carbonitrile 25 and trans-2-
acetoxymethyl-1-(4-chlorobenzyl)-4-phenylpiperidin-4-carbonitrile 26 in a ratio of 71-79/21-29 
(25/26). Subsequently, acetates 25 and 26 were redissolved in MeOH, after which lithium hydroxide 
(1.3 mmol, 2 equiv) was added and the resulting solution was heated under reflux for 1 hour. 
Afterwards, the reaction mixture was poured into water (10 ml) and extracted with Et2O (3 × 10 ml). 
Drying (MgSO4), filtration of the drying agent and evaporation of the solvent in vacuo afforded a 
mixture of trans-1-(4-chlorobenzyl)-6-hydroxy-4-phenylazepane-4-carbonitrile 27 and trans-1-(4-
chlorobenzyl)-2-hydroxymethyl-4-phenylpiperidin-4-carbonitrile 28 in a 71-79/21-29 (27/28) ratio. 
The major constituent, trans-1-(4-chlorobenzyl)-6-hydroxy-4-phenylazepane-4-carbonitrile 27, was 
isolated in pure form by means of column chromatography on silica gel (hexane/EtOAc 1/1). 
Alternative procedure: To a solution of trans-1-(4-chlorobenzyl)-2-chloromethyl-4-phenylpiperidine-
4-carbonitrile 11c (0.95 mmol) in ethanol (10 ml), sodium acetate (1.9 mmol, 2 equiv) was added and 
the resulting solution was placed in a 80 ml sealed glass vessel, provided with an appropriate stirring 
bar and subjected to microwave conditions (110°C, 20 minutes). Afterwards, the reaction mixture 
was poured into water (10 ml) and extracted with Et2O (3 × 10 ml). Drying (MgSO4), filtration of the 
drying agent and evaporation of the solvent in vacuo afforded trans-6-acetoxy-1-(4-chlorobenzyl)-4-
phenylazepane-4-carbonitrile 25 and trans-2-acetoxymethyl-1-(4-chlorobenzyl)-4-phenylpiperidin-4-
carbonitrile 26 in a ratio of 71-79/21-29 (25/26). Subsequently, acetates 25 and 26 were redissolved 
in MeOH, after which lithium hydroxide (1.3 mmol, 2 equiv) was added and the resulting solution 
was heated under reflux for 1 hour. Afterwards, the reaction mixture was poured into water (10 ml) 
and extracted with Et2O (3 × 10 ml). Drying (MgSO4), filtration of the drying agent and evaporation of 
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the solvent in vacuo afforded a mixture of trans-1-(4-chlorobenzyl)-6-hydroxy-4-phenylazepane-4-
carbonitrile 27 and trans-1-(4-chlorobenzyl)-2-hydroxymethyl-4-phenylpiperidin-4-carbonitrile 28 in 
a ratio of 71-79/21-29 (27/28). The major constituent, trans-1-(4-chlorobenzyl)-6-hydroxy-4-
phenylazepane-4-carbonitrile 27, was isolated in pure form by means of column chromatography on 
silica gel (hexane/EtOAc 1/1).trans-1-(4-Chlorobenzyl)-6-hydroxy-4-phenylazepane-4-carbonitrile 
27. (55%) Yellow oil. Rf = 0.29 (hexane/EtOAc 3/1). 
1H NMR (CDCl3): δ 2.02-2.07 (2H, m); 2.15-2.40 
(2H, m); 2.41 (1H, dd, J = 14.3, 5.0, 1.1 Hz); 2.83-2.91 (3H, m); 3.01 (1H, dd, J = 13.2, 3.3 Hz); 3.65 (1H, 
d, J = 13.5 Hz); 3.71 (1H, d, J = 13.5 Hz); 4.06-4.17 (1H, m); 7.24-7.51 (9H, m). 13C NMR (CDCl3); δ 40.7 
(CH2); 43.6 (C); 47.7 (CH2); 52.8 (CH2); 59.8 (CH2); 62.6 (CH2); 68.3 (CH); 122.6 (C); 125.2 (CH); 127.9 
(CH); 128.7 (CH); 129.2 (CH); 130.4 (CH); 133.1 (C); 137.5 (C); 142.6 (C). IR (cm-1): νOH = 3422 νCN = 
2236. MS (70 eV): m/z (%): 341/3 (M++1, 100). Anal. Calcd for C20H21ClN2O: C 70.48; H 6.21; N 8.22. 
Found: C 70.74; H 6.49; N 8.08. 
trans-1-(4-Chlorobenzyl)-2-hydroxymethyl-4-phenylpiperidine-4-carbonitrile 28. Spectral data 
derived from a mixture of nitriles 27 and 28. Yellow oil. Rf = 0.16 (hexane/EtOAc 9/1). 
1H NMR 
(CDCl3): δ 1.92-2.10 (2H, m); 2.36 (2H, d, J = 5.0 Hz); 2.55 (1H, dt, J = 11.7, 4.0 Hz); 2.78-3.01 (2H, m); 
3.16 (1H, d, J = 13.8 Hz); 3.51 (1H, d (broad), J = 11.0 Hz); 3.98 (1H, dd, J = 11.0, 3.3 Hz); 4.17 (1H, d, J 
= 13.8 Hz); 7.23-7.49 (9H, m). 13C NMR (CDCl3); δ 35.7 (CH2); 39.8 (CH2); 43.0 (C); 49.6 (CH2); 57.0 
(CH2); 60.0 (CH); 62.9 (CH2); 122.2 (C); 125.6 (CH); 128.4 (CH); 128.8 (CH); 129.2 (CH); 130.3 (CH); 
133.1 (C); 137.0 (C); 139.9 (C). IR (cm-1): νOH=3423 νCN=2234. MS (70 eV): m/z (%): 341/3 (M
++1, 100). 
 
Synthesis of 2-arylmethyl-5-phenyl-2,7-diazabicyclo[3.3.1]nonanes 29. As a representative example, 
the synthesis of 2-(4-methylbenzyl)-5-phenyl-2,7-diazabicyclo[3.3.1]nonane 29b is described here. To 
a solution of cis-1-(4-methylbenzyl)-2-chloromethyl-4-phenylpiperidine-4-carbonitrile 9b (0.6 mmol) 
in dry THF (10 ml), LiAlH4 (1.2 mmol, 2 equiv) was added and the resulting solution was heated under 
reflux for 2 hours under nitrogen atmosphere. The reaction mixture was poured into water (10 ml) 
and extracted with Et2O (3 × 10 ml). Drying (MgSO4), filtration of the drying agent, and evaporation of 
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the solvent in vacuo afforded 2-(4-methylbenzyl)-5-phenyl-2,7-diazabicyclo[3.3.1]nonane 29b, which 
was purified through crystallization from Et2O/hexane (1/1). 2-(4-Methylbenzyl)-5-phenyl-2,7-
diazabicyclo[3.3.1]nonane 29b. (75%) White Crystals. Mp = 110.3°C. 1H NMR (CDCl3): δ 1.92-2.03 
(2H, m); 2.13-2.27 (2H, m); 2.34 (3H, s); 2.65 (1H, dd, J = 12.9, 1.9 Hz); 2.80-2.90 (3H, m); 3.27 (1H, dd, 
J = 12.7, 2.8 Hz); 3.39-3.49 (2H, m); 3.73 (1H, d, J = 13.2 Hz); 3.78 (1H, d, J = 13.2 Hz); 7.11-7.36 (9H, 
m). 13C NMR (CDCl3); δ 21.3 (CH3); 35.4 (C); 37.1 (CH2); 37.4 (CH2); 46.4 (CH2); 49.7 (CH2); 52.1 (CH); 
58.7 (CH2); 60.0 (CH2); 125.1 (CH); 126.1 (CH); 128.4 (CH); 128.9 (CH); 129.1 (CH); 136.5 (C); 136.6 (C); 
149.2 (C). IR (cm-1): νNH2 = 3336. MS (70 eV): m/z (%): 307 (M
++1, 100). Anal. Calcd for C21H26N2: C 
82.31; H 8.55; N 9.14. Found: C 82.39; H 8.63; N 9.02. 
 
Synthesis of tert-butyl 2-(4-methylbenzyl)-5-phenyl-2,7-diazabicyclo[3.3.1]nonane-7-carboxylate 
30. To a solution of 2-(4-methylbenzyl)-5-phenyl-2,7-diazabicyclo[3.3.1]nonane 29b (0.2 mmol) in dry 
CH2Cl2 (10 ml), Boc2O (0.22 mmol, 1.1 equiv), pyridine (0.22 mmol, 1.1 equiv) and DMAP (0.022 
mmol, 0.1 equiv) were added, and the resulting solution was stirred at room temperature for 3 
hours. The reaction mixture was poured into brine (10 ml) and extracted with CH2Cl2 (3 × 10 ml). 
Drying (MgSO4), filtration of the drying agent and evaporation of the solvent in vacuo afforded tert-
butyl 2-(4-methylbenzyl)-5-phenyl-2,7-diazabicyclo[3.3.1]nonane-7-carboxylate 30, which was 
isolated in pure form by means of column chromatography on silica gel (hexane/EtOAc 3/1). tert-
Butyl 2-(4-methylbenzyl)-5-phenyl-2,7-diazabicyclo[3.3.1]nonane-7-carboxylate 30. (90%) Yellow 
oil. 1H NMR (CDCl3): δ 1.57 (9H, s); 1.82-2.03 (2H, m); 2.11-2.25 (2H, m); 2.33 (3H, s); 2.63-2.81 (3H, 
m); 2.96-3.07 (2H, m); 3.75 (2H, 2×d, J = 14.3 Hz); 4.55 (2H, d, J = 13.2 Hz); 7.12-7.38 (9H, m). 13C NMR 
(CDCl3); δ 21.2 (CH3); 28.9 (CH3); 35.5 (C); 37.0 (CH2); 38.0 (CH2); 42.8 (CH2); 48.1 (CH2); 50.8 (CH); 53.2 
(CH2); 60.0 (CH2); 79.8 (C); 125.2 (CH); 126.6 (CH); 128.6 (CH); 128.8 (CH); 129.2 (CH); 136.0 (C); 136.7 
(C); 147.4 (C); 154.3 (C). IR (cm-1): νCO = 1687. MS (70 eV): m/z (%): 407 (M
++1, 100). Anal. Calcd for 
C26H34N2O2: C 76.81; H 8.43; N 6.89. Found: C 77.06; H 8.71; N 6.98. 
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Synthesis of trans-4-aminomethyl-1-arylmethyl-2-methyl-4-phenylpiperidine 31. As a 
representative example, the synthesis of trans-4-aminomethyl-2-methyl-1-(4-methylbenzyl)-4-
phenylpiperidine 31b is described here. To a solution of trans-2-chloromethyl-1-(4-methylbenzyl)-4-
phenylpiperidine-4-carbonitrile 11b (0.6 mmol) in dry THF (10 ml), LiAlH4 (1.2 mmol, 2 equiv) was 
added and the resulting solution was heated under reflux for 2 hours under nitrogen atmosphere. 
The reaction mixture was poured into water (10 ml) and extracted with Et2O (3 × 10 ml). Drying 
(MgSO4), filtration of the drying agent and evaporation of the solvent afforded trans-4-aminomethyl-
2-methyl-1-(4-methylbenzyl)-4-phenylpiperidine 31b, which was isolated in pure form by means of 
column chromatography on silica gel (CH2Cl2/MeOH 94/6). trans-4-Aminomethyl-2-methyl-1-(4-
methylbenzyl)-4-phenylpiperidine 31b. (65%) Yellow oil. Rf = 0.06 (CH2Cl2/MeOH 94/6). 
1H NMR 
(CDCl3): δ 1.23 (1H, d, J = 6.1 Hz); 1.67 (1H, dd, J= 13.2, 11.6 Hz); 1.81 (1H, dt, J = 13.1, 3.8 Hz); 2.00 
(1H, dd, J = 13.2, 2.8 Hz); 2.07 (1H, dt, J = 13.1, 2.5 Hz); 2.24 (1H, dt, J = 12.1, 2.5 Hz); 2.33 (3H, s); 
2.54-2.60 (1H, m); 2.75 (1H, dt, J = 12.1, 3.8 Hz); 2.92 and 2.98 (2H, 2×d, J = 12.9 Hz); 3.17 (2H, d, J = 
13.2 Hz); 4.08 (2H, d, J = 13.2 Hz); 7.10-7.34 (9H, m). 13C NMR (CDCl3); δ 21.2 (CH3); 21.6 (CH3); 32.3 
(CH2); 41.0 (C); 42.6 (CH2); 47.5 (CH2); 48.2 (CH2); 52.5 (CH); 57.8 (CH2); 125.9 (CH); 126.1 (CH); 128.4 
(CH); 129.0 (CH); 129.2 (CH); 135.9 (C); 136.5 (C); 147.6 (C). IR (cm-1): νNH2 = 3370. MS (70 eV): m/z 
(%): 309 (M++1, 100). Anal. Calcd for C21H28N2: C 81.77; H 9.15; N 9.08. Found: C 81.95; H 9.32; N 8.98. 
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